Numinus Wellness Inc. Stock Price, News & Analysis

Numinus Wellness Inc. (TSX: NUMI) has launched a new client website as part of its branding strategy to unify its wellness clinics under one brand. The enhanced website aims to improve client experience with better navigation and appointment booking tools, fostering a supportive environment for those seeking mental health treatments. The site incorporates geo-location technology, reflecting available services in users' regions, especially amid varying timelines for regulatory approvals for MDMA and psilocybin-assisted therapies. This initiative aligns with Numinus's goal of expanding digital services and strengthening its platform for practitioner training and client support, ultimately driving growth in the psychedelic-assisted therapy sector.

Numinus Wellness reported substantial financial growth in Q2 2023, with revenues soaring by 581.1% year-over-year to $5.4 million. Gross profit increased by 820.9% to $2.1 million, alongside a rise in gross margin to 39.3% from 29.1% in Q2 2022. Despite a slight sequential revenue decline of 5.5% due to seasonal impacts, the company's cash position remains robust at $19.7 million. The recent acquisition of Novamind contributed significantly to growth, and the firm is advancing a new licensing model to lower expansion costs. Numinus also plans to enhance its digital platforms for better practitioner training and client support, positioning itself as a leader in psychedelic-assisted therapies.

Numinus Wellness has launched a new clinic licensing model called the Numinus Network, allowing independent practitioners to operate clinics under its brand. This model aims to reduce capital investment while expanding access to psychedelic-assisted therapies across North America. The company has partnered with Healing Commercial Real Estate Inc. to provide licensees with turn-key locations, enhancing operational support and clinic infrastructure. Numinus aims to advocate for more accessible treatment options, compelling practitioners to join their network while retaining independence. The licensing fees and investment costs will vary based on individual arrangements and locations.

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will announce its Q2 2023 financial results on April 13, 2023, after market close. A conference call and webcast will follow at 5:30 p.m. Eastern time, where executives will discuss company performance and recent initiatives. Interested participants can register for the live webcast here. A replay will be available post-event until April 27, 2023. Numinus, focused on evidence-based psychedelic-assisted therapies, aims to transform mental health care by integrating these therapies into mainstream practice.

Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) has launched the Numinus Certification Pathway, a comprehensive training program for psychedelic-assisted therapy (PAT). This initiative includes courses that develop core PAT skills through various teaching methods, ensuring practitioners gain competency in using psychedelic medications. Notably, over 200 practitioners have already participated in Numinus training since its inception in Fall 2022. The most sought-after course, The Fundamentals of Psychedelic-Assisted Therapy, begins its next intake in May 2023, emphasizing evidence-based care and safety. The program aims to enhance the quality of mental health services provided by trained professionals.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) will participate in the Sequire Cannabis & Psychedelics Conference on April 5, 2023. The company's Founder and CEO, Payton Nyquvest, is set to present at 10:00 a.m. ET. Interested attendees can register for the virtual event here.

Numinus specializes in innovative mental health treatments, including psychedelic-assisted therapies, to promote healing for conditions such as depression, anxiety, and trauma. For more information, contact invest@numinus.com.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced contributions from Chief Clinical Officer Reid Robison, who published four peer-reviewed papers in 2023 about innovative mental health treatments. These studies focus on conditions such as PTSD, depression, and anxiety, showcasing advancements in psychedelic-assisted therapies. Key highlights include the effectiveness of ketamine-assisted psychotherapy for healthcare workers with PTSD, the positive impact of cannabis-assisted psychotherapy, and promising breathwork interventions for anxiety. Numinus aims to integrate evidence-based treatments into mainstream clinical practice, propelling the mental health sector forward.

Numinus Wellness Inc. (TSX: NUMI; OTCQX: NUMIF) will be featured at the upcoming South by Southwest Conference in Austin, Texas, from March 10 to 19, 2023. CEO Payton Nyquvest will be on a panel titled "Music as Medicine: Music as a Tool For Healing" on March 10 at 4:00 PM CT. The discussion will focus on the role of music in psychedelic healing, highlighting its importance in therapy. This event is part of Numinus' Music as Medicine program, which emphasizes the connection between music and mental health. Numinus aims to advance innovative, evidence-based psychedelic-assisted therapies for mental health care.

Numinus Wellness (TSX: NUMI; OTCQX: NUMIF) announced Dr. Paul Thielking, Chief Science Officer, will join a Water Tower Research Fireside Chat on February 28, 2023, at 3:00 p.m. ET. The discussion will cover Numinus' clinical research activities at Cedar Clinical Research and the new research site in Phoenix, Arizona. This engagement highlights Numinus' commitment to advancing evidence-based psychedelic-assisted therapies aimed at improving mental health. Interested parties can register here.